New Retina Radio is a place to hear stories about retina that are told nowhere else.
Tips for Mastering Secondary IOLs
No two secondary IOL procedures are the same, and each case requires your full attention. What is your favorite technique? How are you protecting the haptics and avoiding hypotony? Hear from four of the top retina surgeons on their preferred approaches and how they avoid common surgical pitfalls.
A conversation with Christina Y. Weng, MD, MBA; Ashkan M. Abbey, MD; María H. Berrocal, MD; and Omesh P. Gupta, MD, MBA
New Retina Radio Journal Club: Profiling Punctate Inner Choroidopathy-like Reactions
Punctate inner choroidopathy-like, or PIC-like, reactions are rare, and they sometimesl confound retina specialists. New Retina Radio Journal Club with VBS panelists Kyle Kovacs, MD, and Priya Vakharia, MD, join moderator Yasha Modi, MD, to review a retrospective observational study of patients with PIC-like presentations in unrelated chorioretinal disorders.
AAO '22: Biosimilars’ Practice Implications and Year 2 of YOSEMITE/RHINE
Two biosimilars have been approved by the US FDA, and more are going to receive approval soon. With this level of disruption in US retina practice, what do you need know? George Williams, MD, the Senior Secretary for Advocacy at the AAO, joined us for preview on what practice might look like now that biosimilars are a fact of life. Also, Caroline Baumal, MD, sat down with us to discuss the YOSEMITE and RHINE studies, which released 2-year results. How did patients receiving faricimab (Vabysmo, Genentech/Roche) respond during their second year of treatment?
Innovations in Retinal Imaging
John Kitchens, MD, invites Aleksandra Rachitskaya, MD, and Jonathan Russell, MD, PhD, to discuss the use of imaging technology in the retina clinic. The surgeons discuss cases in which they share approaches to imaging to evaluate wet age-related macular degeneration, retinal detachments, and more. They explain the value of OCT, ultra-widefield imaging, and fluorescein angiography, and comment on the use of change analysis with the Cirrus 6000 and Retina Workplace. Finally, the trio provides insights into the potential future of imaging technology. This podcast is sponsored by ZEISS.
AAO '22 Late-Breaking Talks: Gene Therapies for GA and XLRP
We know about long-term intravitreal injections that might slow the progression of geographic atrophy (GA). But could a gene therapy in the pipeline require fewer treatments and still yield results? Jeffrey Heier, MD, summarized an AAO presentation on the phase 1 data of JNJ-1887 (Janssen), a potential gene therapy for GA. Was it safe—and were there signs of efficacy? Michel Michaelides, BSc, MB,, BS MD(Res), FRCOphth, joined us to speak about a gene therapy targeting x-linked retinitis pigmentosa. With a phase 3 study for the drug AAV5-RPGR (Jannsen/MeiraGTx) already underway, what can we learn from earlier trial results?
New Retina Radio Journal Club: Biosimilars in Retina: A Pair of Phase 3 Papers
Two biosimilars have been approved for retinal indications. What conclusions were drawn from the phase 3 studies that preceded their approval? Yasha Modi, MD, is joined by Kyle Kovacs, MD, and Priya Vakharia, MD, to review the ins and outs of biosimilarity, discuss the findings of two recent papers, and consider how use of biosimilars might affect future clinical practice in the United States.
I have yet to hear information regarding retinitis pigmentosa! 😩 have advanced arRP. Need stem cell and crisper. Rare gene (RP59) small enough for gene therapy but I’m too advanced for gene therapy. Traveled all over the world, including Japan. Will do ANYTHING to be in a clinical trial. Please help. Only 37.
June 22, 2020 podcast!!!
The one about $LCTX is very interesting!!
Awesome podcast! Very relevant for retina surgeons. John Kitchens is a master interviewer and moderator.